(4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6-sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders

Abstract

Disclosed are compounds of formula (I) wherein Gis as antagonists of the muscarinic acetylcholine receptor M(mAChR M) for use in the treatment of e.g. a neurodegenerative disorder, a movement disorder, or a brain disorder, such as e.g. Parkinson's disease, drug-induced Parkinsonism, dystonia, Tourette's syndrome, dyskinesias, schizophrenia, cognitive deficits associated with schizophrenia, excessive daytime sleepiness, attention deficit hyperactivity disorder (ADHD), Huntington's disease, chorea, cerebral palsy, and progressive supranuclear palsy. An exemplary compound is e.g. (2,5-difluoro-4-(6-(((3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-λ-sulfanone (e.g. example 12; compound no. 7) Pharmacological data on the activity of the compounds in an mAChR Mcell-based assay are provided (e.g. table 2).